RPRX ▼ -5.7% - Royalty Pharma plc $RPRX - Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Royalty Pharma fell 5.7% after announcing an update on Novartis' Phase 3 topline results for pelacarsen, a cardiovascular therapy in which the company holds royalty rights. The stock decline suggests the trial results or their commercial implications disappointed investors who were banking on strong efficacy data to drive future royalty payments from the drug. 04-SEP-2026 07:05 PM ET